Table 1

The league table of network meta-analysis for ORR according to all interventions

OR 95% CrIs
Bev_DDP
3.19 (2.11, 4.92)*DDP
0.85 (0.53, 1.37)0.27 (0.22, 0.33)*Endo_DDP
0.16 (0.05, 0.53)* 0.05 (0.02, 0.15)* 0.19 (0.06, 0.59)* Endo_LBP
0.25 (0.09, 0.68)* 0.08 (0.03, 0.2)* 0.29 (0.11, 0.75)* 1.54 (0.35, 6.84)Endo_NDP
0.92 (0.4, 2.03)0.29 (0.14, 0.56)* 1.08 (0.52, 2.18)5.69 (2.37, 14.65)* 3.73 (1.17, 12.04)* LBP
0.81 (0.38, 1.71)0.25 (0.13, 0.46)* 0.95 (0.49, 1.81) 5.06 (1.39, 19.02)* 3.28 (1.65, 6.76)* 0.88 (0.35, 2.24)NDP
  • ORs between the included interventions according to the results of network meta-analysis.

  • Data bolded in black indicate they are from an indirect comparison.

  • *p<0.05.

  • Bev_DDP, bevacizumab+cisplatin; CrIs, credible intervals; Endo_DDP, endostar+cisplatin; Endo_LBP, endostar+lobaplatin; Endo_NDP, endostar+nedaplatin; ORR, objective response rate.